Hyperliquid Strategies Inc. (HSI), formed from an $888 million reverse merger between Sonnet Biotherapeutics Holdings Inc. and Rorschach I LLC, has filed a Form S-1 registration with the U.S. Securities and Exchange Commission (SEC) to raise up to $1 billion through an offering of 160 million shares of common stock. Hyperliquid Strategies Files $1B IPO, [...]